Hedley, P. L., Jørgensen, P., Schlamowitz, S., Moolman-Smook, J., Kanters, J. K., Corfield, V. A.; Christiansen, M., « The genetic basis of Brugada syndrome: A mutation update. », Hum. Mut., vol. 30, no 9, , p. 1256–1266 (DOI10.1002/humu.21066)
nih.gov
ncbi.nlm.nih.gov
Hinse, C.; Stöckigt, J., « The structure of the ring-opened N beta-propyl-ajmaline (Neo-Gilurytmal) at physiological pH is obviously responsible for its better absorption and bioavailability when compared with ajmaline (Gilurytmal). », Pharmazie., vol. 55, no 7, , p. 531–2 (PMID10944783)
Kiesecker, C.; Zitron E.; Lück S.; Bloehs R.; Scholz E.P.; Kathöfer S.; Thomas D.; Kreye V.A.; Katus H.A.; Schoels W.; Karle C.A.; Kiehn J.., « Class Ia anti-arrhythmic drug ajmaline blocks HERG potassium channels: mode of action. », Naunyn Schmiedebergs Arch Pharmacol., vol. 370, no 6, , p. 423–35 (PMID15599706)
Rolf, S.; Bruns, H.J.; Wichter, T.; Kirchhof, P.; Ribbing, M.; Wasmer, K.; Paul, M.; Breithardt, G.; Haverkamp, W.; Eckardt, L., « The ajmaline challenge in Brugada syndrome: Diagnostic impact, safety, and recommended protocol. », EUR HEART J, vol. 24, no 12, , p. 1104–1112 (PMID12804924)
Wellens H.J.; Bär F.W.;, Gorgels A.P.; Vanagt E.J., « Use of ajmaline in patients with the Wolff-Parkinson-White syndrome to disclose short refractory period of the accessory pathway. », Am J Cardiol., vol. 45, no 1, , p. 130–3 (PMID7350760)
Manz M.; Lüderitz B., « Emergency therapy of ventricular tachycardias: lidocaine versus ajmaline. », Dtsch Med Wochenschr., vol. 113, no 34, , p. 1317–21 (PMID3044723)
